Allergy Immunotherapy Advances: HDM Market Analysis

DelveInsight’s “Diabetes Pipeline Insight 2026” report delivers extensive analysis covering 200+ pharmaceutical companies and 200+ investigational drugs within the Diabetes development landscape. The report encompasses comprehensive Diabetes drug candidate profiles spanning both clinical and preclinical development phases. Additionally, it includes therapeutic evaluation categorized by product classification, developmental stage, administration route, and molecular structure. The report also spotlights dormant pipeline candidates in this therapeutic area.

Explore the newest medications and therapeutic approaches in the Diabetes Pipeline @ Diabetes Pipeline Outlook

Key Highlights from the Diabetes Pipeline Report

• On March 11, 2026, Alnylam Pharmaceuticals launched a study to assess the impact of a single administration of ALN-4324 on systemic insulin sensitivity in subjects with T2DM.
• In January 2026, BioXTek initiated a clinical study assessing the Effectiveness of Placental Membrane Dressings in Expediting Diabetic Foot Healing When Compared to Matched Historical Controls Receiving Standard Treatment.
• DelveInsight’s Diabetes pipeline analysis reveals a dynamic environment with 200+ engaged participants advancing 200+ investigational therapeutics for Diabetes management.
• The prominent Diabetes Companies include vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., and numerous others.
• Notable Diabetes Therapeutics include Aspirin, DA-2811, Forxiga, TG103, and additional candidates.

Gain knowledge about Diabetes Clinical Studies, novel therapies, and prominent companies with DelveInsight @ Diabetes Treatment Drugs

The Diabetes Pipeline Report delivers a disease synopsis, pipeline landscape, and therapeutic evaluation of crucial pipeline medications in this sector. The Diabetes Pipeline Report additionally emphasizes the unaddressed medical needs regarding Diabetes.

Diabetes Overview

Diabetes represents a chronic metabolic condition characterized by elevated blood glucose levels resulting from the body’s failure to produce or properly utilize insulin, a hormone critical for glucose regulation. The condition principally manifests in two primary forms: Type 1 diabetes, an autoimmune disorder where the immune system destroys insulin-producing cells within the pancreas, and Type 2 diabetes, which is more prevalent and frequently linked with insulin resistance and lifestyle elements including obesity and inadequate nutrition. Additional types encompass gestational diabetes, which develops during pregnancy, and less common forms such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).

Diabetes Emerging Drugs Profile

• Cadisegliatin: vTv Therapeutics

Cadisegliatin, alternatively designated as TTP399, is an innovative oral agent developed by vTv Therapeutics, formulated as a liver-selective glucokinase activator. It is intended to function as an adjunctive treatment to insulin for patients with type 1 diabetes (T1D). This medication has gained recognition for its capability to enhance glycemic management by promoting hepatic glucose absorption and glycogen accumulation independent of insulin, addressing a vital requirement in diabetes care. Presently, the drug is undergoing Phase III clinical evaluation for the management of Diabetes.

• LY-3209590: Eli Lilly and Company

Insulin efsitora alfa (LY3209590) represents a once-weekly basal insulin formulation, a fusion protein that merges a novel single-chain insulin variant with a human IgG2 Fc domain. It is engineered specifically for once-weekly subcutaneous delivery, and with its minimal peak-to-trough fluctuation, it possesses the capacity to deliver more consistent glucose concentrations (reduced glucose variation) across the week. Efsitora is currently in phase III advancement for adults diagnosed with type 1 and 2 diabetes.

• CT-388: Roche

CT-388 is a once-weekly subcutaneous administration, dual GLP-1/GIP receptor agonist under development for managing obesity and type 2 diabetes (T2D). CT-388 was engineered to demonstrate robust activity on both the GLP-1 and GIP receptors while exhibiting minimal to negligible β-arrestin recruitment on either receptor. This biased signaling substantially reduces receptor internalization and subsequent desensitization, which is anticipated to result in extended pharmacological activity. Presently, the drug is in Phase II clinical evaluation for the management of Type 2 Diabetes Mellitus.

• HU6: Rivus Pharmaceuticals

HU6 is an investigational, first-in-class oral medication developed by Rivus Pharmaceuticals. It represents a novel drug class termed Controlled Metabolic Accelerators (CMAs), which are formulated to selectively enhance fat metabolism, promoting fat reduction while maintaining muscle mass. HU6 operates by gently elevating resting metabolism, specifically by triggering a mechanism called mitochondrial uncoupling. This mechanism enhances the oxidation of carbohydrates and fats without diminishing ATP (energy) generation, yielding the selective elimination of accumulated fat across the body. Presently, the drug is in the Phase II developmental stage to address Diabetes.

• XW014: Sciwind Biosciences

XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist created by Sciwind Biosciences for managing obesity and Diabetes (T2D). XW014 operates as a GLP-1 receptor agonist, which indicates it replicates the function of the GLP-1 hormone that is secreted following meals. This hormone serves a crucial function in controlling glucose metabolism by enhancing insulin secretion, suppressing glucagon release, and encouraging satiety. As an oral small molecule, XW014 provides benefits over conventional peptide-based GLP-1 treatments, such as simplified administration and the capability for combination regimens with other oral agents. Presently, the drug is in Phase I clinical evaluation for the management of Diabetes.

• K-833: Kallyope Inc.

K-833 is an investigational oral small-molecule created by Kallyope Inc., formulated as a nutrient receptor agonist for managing obesity and type 2 diabetes. K-833, frequently evaluated in combination with Kallyope’s additional candidate K-757, activates G-protein coupled receptors (specifically GPR119), which participate in the secretion of hormones that reduce appetite and control glucose. Presently, the drug is in Phase I clinical evaluation for the management of Diabetes.

Discover revolutionary therapies and clinical studies in the Diabetes Pipeline @ New Diabetes Drugs

The Diabetes Pipeline Report Provides Insights into

• The report delivers comprehensive insights about pharmaceutical companies that are advancing therapies for managing Diabetes with cumulative therapeutics developed by each organization for the same indication.
• It evaluates the various therapeutic candidates organized into early-stage, mid-stage, and late-stage of advancement for Diabetes Management.
• Diabetes Companies are engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) initiatives.
• Diabetes Drugs in development are categorized by the developmental stage, administration route, target receptor, monotherapy or combination regimen, various mechanisms of action, and molecular classification.
• Comprehensive analysis of partnerships (company-company partnerships and company-academia partnerships), licensing arrangements and funding details for future progression of the Diabetes market

Diabetes Companies

vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and numerous others.

The Diabetes pipeline report delivers the therapeutic evaluation of the pipeline medications by the Route of Administration. Products have been organized under various ROAs including

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diabetes Products have been organized under various Molecular types including,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover new medications, pipeline advancements, and key companies with DelveInsight’s professional analysis @ Diabetes Market Drivers and Barriers

Scope of the Diabetes Pipeline Report

• Coverage- Global
• Diabetes Companies- vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and numerous others.
• Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and additional candidates.
• Diabetes Therapeutic Evaluation by Product Type: Mono, Combination, Mono/Combination
• Diabetes Therapeutic Evaluation by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access DelveInsight’s comprehensive pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs

Table of Contents

• Introduction
• Executive Summary
• Diabetes: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Diabetes- DelveInsight’s Analytical Perspective
• Late Stage Products (Phase III)
• Cadisegliatin: vTv Therapeutics
• Drug profiles in the comprehensive report…..
• Mid-Stage Products (Phase II)
• CPL207280: Celon Pharma
• Drug profiles in the comprehensive report…..
• Early Stage Products (Phase I)
• KN056: Suzhou Alphamab Co., Ltd.
• Drug profiles in the comprehensive report…..
• Preclinical and Discovery Stage Products
• Drug name: Company name
• Drug profiles in the comprehensive report…..
• Inactive Products
• Diabetes Key Companies
• Diabetes Key Products
• Diabetes- Unmet Needs
• Diabetes- Market Drivers and Barriers
• Diabetes- Future Perspectives and Conclusion
• Diabetes Analyst Views
• Diabetes Key Companies
• Appendix

About Us

DelveInsight is a premier healthcare-focused market research and consulting organization that delivers clients with superior market intelligence and analysis to facilitate informed business strategies. With a team of seasoned industry professionals and a thorough understanding of the life sciences and healthcare domains, we provide customized research solutions and insights to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to remain ahead of the growth trajectory.

Contact Us

Kanishk

kkumar@delveinsight.com 

 

DelveInsight’s comprehensive “Psoriasis Pipeline Insight, 2026” analysis delivers in-depth intelligence on over 65 organizations and more than 75 developmental therapeutics within the Psoriasis treatment landscape. The report encompasses detailed profiles of Psoriasis pipeline candidates across both clinical and preclinical development phases. Additionally, it presents a thorough evaluation of Psoriasis therapeutic candidates by product category, developmental phase, administration method, and molecular classification. The analysis also identifies dormant pipeline assets within this therapeutic area.

Explore our cutting-edge pipeline analysis today! @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

Main Highlights from the Psoriasis Pipeline Analysis

• On February 25, 2026 – Alumis Inc. launched an investigation after participants completed either parent study ESK-001-016 or ESK-001-017. Participants will be administered open-label ESK-001 twice daily over a 24-week period. Following this initial phase, the first 200 participants achieving a minimum PASI-75 clinical response will be randomized to either ESK-001 or placebo groups. Throughout this period, participants experiencing loss of initial clinical response may resume open-label ESK-001 therapy. Those completing Week 48 will transition back to open-label ESK-001 and continue treatment until study conclusion or withdrawal. All other participants failing to meet randomized withdrawal phase criteria will maintain open-label ESK-001 therapy throughout the remaining study duration.
• On February 24, 2026 – AbbVie revealed plans for a study evaluating the safety and efficacy of risankizumab in adult subjects presenting with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. The study will track adverse events alongside changes in disease manifestations and symptoms.
• DelveInsight’s Psoriasis pipeline analysis reveals a dynamic landscape featuring more than 65 active organizations developing over 75 pipeline therapeutics for Psoriasis management.
• Key Psoriasis Industry Players include Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc., among others.
• Notable Psoriasis Pipeline Candidates include Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and additional therapeutics.

Access the latest updates and join the transformation in Immunological and Autoimmune Disorders management @ Psoriasis Clinical Trials Assessment

Psoriasis Investigational Drug Profiles

Piclidenoson: Can-Fite Biopharma

Piclidenoson, also identified as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), represents an orally administered small molecule compound available in tablet formulation. The therapeutic mechanism of Piclidenoson operates through A3AR mediation, involving the modulation of critical signaling proteins including PI3K, PKA, PKB/Akt, IKK, and NF-kB. This results in dysregulation of the Wnt/β-catenin pathway and suppression of inflammatory cytokine generation. Presently, this therapeutic candidate is undergoing Phase III development for Psoriasis treatment.

Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is an investigational Nanobody® engineered by MoonLake Immunotherapeutics for inflammatory disease management. This therapeutic agent targets both IL-17A and IL-17F cytokines, blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimer formations, while incorporating a domain that binds human albumin to improve tissue penetration. During Phase 2 clinical evaluation, sonelokimab exhibited enhanced efficacy versus AbbVie’s Humira in psoriatic arthritis management, demonstrating elevated patient response rates in joint swelling reduction and psoriasis severity improvement. Furthermore, the candidate showed encouraging outcomes in hidradenitis suppurativa treatment, achieving the HiSCR75 endpoint during the Phase 2 MIRA study. Currently, MoonLake is executing Phase III studies for both indications while investigating potential applications in additional inflammatory conditions including palmoplantar pustulosis and axial spondyloarthritis.

QY101: E-nitiate Biopharmaceuticals

QY101 represents a topical ointment formulation created by E-nitiate Biopharmaceuticals for managing inflammatory dermatological conditions such as atopic dermatitis and plaque psoriasis. This therapeutic operates as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) antagonist, designed to decrease inflammation through targeting hyperactive PDE4 signaling pathways. Preclinical investigations have revealed favorable pharmacokinetic properties, robust efficacy, and excellent safety profiles, establishing its appropriateness for diverse patient populations, including pediatric cases. Presently, QY101 is advancing through Phase II clinical evaluation in China for plaque psoriasis management, subsequent to completing Phase I trials in healthy participants. The organization is additionally pursuing alternative formulations, including an inhalation delivery system, via licensing partnerships.

SFA 002: SFA Therapeutics

SFA-002, functioning as an IL-10 up-regulator within immune cells, is advancing toward Phase 2 clinical evaluation and has exhibited encouraging Phase 1a and Phase 1b outcomes for psoriasis management. SFA-002 achieved its primary safety endpoint during Phase 1b clinical evaluation. No treatment-associated adverse events or toxicities were detected throughout the treatment interval, with no rebound phenomena observed. SFA Therapeutics has submitted its annual safety update to the U.S. Food and Drug Administration. SFA-002 successfully met its exploratory efficacy endpoint. Subjects receiving SFA-002 exhibited statistically significant improvements in Psoriasis Area and Severity Index (PASI) percentage reduction and Investigator Global Assessment (IGA) score enhancement relative to placebo. PASI serves as an instrument for quantifying psoriasis severity and extent, while IGA represents a standardized assessment system for patient disease severity. The investigation utilized two cohorts for evaluating distinct formulations. Currently, this candidate is in Phase II/III development for Psoriasis treatment.

RLS-1496: Rubedo Life Sciences, Inc

RLS-1496 constitutes a first-in-class GPX4 modulator targeting senescent cells and adjacent tissues, under development by Rubedo Life Sciences for dermatological conditions and additional chronic age-associated diseases. This topical medication is engineered to target aging cells, particularly senescent cells, within skin lesions associated with chronic atopic dermatitis and chronic psoriasis. Currently, this therapeutic candidate is in Preclinical development for Psoriasis treatment.

The Psoriasis Pipeline Report Delivers Intelligence On

• The analysis offers comprehensive insights regarding organizations developing therapeutics for Psoriasis management, including aggregate therapeutic candidates developed by individual companies.
• It evaluates diverse therapeutic candidates categorized into early-stage, mid-stage, and late-stage development for Psoriasis treatment.
• Psoriasis-focused Companies engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) programs.
• Psoriasis therapeutic candidates in development are classified by developmental stage, administration route, target receptor, monotherapy versus combination therapy, mechanism of action, and molecular classification.
• Comprehensive evaluation of partnerships (company-to-company and company-to-academia collaborations), licensing agreements, and financing particulars for future advancement of the Psoriasis therapeutic market.

Discover more about Psoriasis therapeutic opportunities in our innovative research and development initiatives @ Psoriasis Unmet Needs

Psoriasis Industry Organizations

Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc., among others.

The Psoriasis Pipeline analysis delivers therapeutic evaluation of pipeline candidates by Administration Route. Therapeutics have been classified under various administration routes including:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Psoriasis therapeutic candidates have been categorized under various molecular classifications including:

• Monoclonal antibody
• Small molecule
• Peptide

Stay updated on our transformation of the Immunological and Autoimmune Disorders landscape @ Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Psoriasis Pipeline Report

• Coverage – Global
• Psoriasis Industry Organizations – Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc., among others.
• Psoriasis Pipeline Candidates – Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and additional therapeutics.
• Psoriasis Therapeutic Evaluation by Product Classification: Monotherapy, Combination, Mono/Combination
• Psoriasis Therapeutic Evaluation by Development Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a comprehensive overview of our recent research discoveries and strategic direction, access the complete Psoriasis Pipeline details on our platform @ Psoriasis Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriasis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Piclidenoson: Can-Fite Biopharma
9. Additional drug profiles in comprehensive report…
10. Mid Stage Products (Phase II/III)
11. SFA 002: SFA Therapeutics
12. Early Stage Products (Phase I/II)
13. Drug Name: Company Name
14. Additional drug profiles in comprehensive report…
15. Preclinical and Discovery Stage Products
16. RLS-1496: Rubedo Life Sciences, Inc
17. Inactive Products
18. Psoriasis Key Companies
19. Psoriasis Key Products
20. Psoriasis – Unmet Needs
21. Psoriasis – Market Drivers and Barriers
22. Psoriasis – Future Perspectives and Conclusion
23. Psoriasis Analyst Views
24. Psoriasis Key Companies
25. Appendix

About DelveInsight

DelveInsight represents a premier healthcare-specialized market research and consulting organization delivering high-quality market intelligence and strategic analysis to support informed decision-making for clients. Supported by a team of seasoned industry professionals and extensive expertise in life sciences and healthcare domains, we deliver tailored research solutions and strategic insights to clients worldwide. Partner with us to access high-quality, precise, and real-time intelligence for maintaining competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com 

 

DelveInsight’s newly published report, “BK Virus Infection Pipeline Insight, 2026,” presents a comprehensive overview of the current clinical development landscape and growth prospects across the BK Virus Infection market. With 10+ key companies actively working to advance 10+ therapeutic candidates, the report delivers in-depth commercial and clinical assessments of pipeline products — from the pre-clinical stage through to the marketed phase. Each drug profile covers mechanism of action, clinical study data, NDA approvals (where applicable), and product development activities including technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product details.

Explore the latest drugs and treatment options advancing in the BK Virus Infection Pipeline access DelveInsight’s full report today: BK Virus Infection Pipeline Outlook

BK Virus Infection: Disease Overview

BK virus (BKV) is a prevalent opportunistic pathogen that poses one of the most significant challenges in kidney transplant medicine, frequently contributing to allograft dysfunction and graft loss. The virus takes its name from a Sudanese kidney transplant recipient — the first documented patient from whom BKV was isolated from the urine, who presented with ureteric stenosis. Classified as a double-stranded circular DNA virus, BKV belongs to the Betapolyomavirus genus within the Polyomaviridae family. Its ability to reactivate in immunocompromised patients makes it a particularly difficult pathogen to manage in post-transplant care settings, highlighting the critical need for dedicated antiviral therapeutic strategies.

Key Highlights from the BK Virus Infection Pipeline Report

• DelveInsight’s BK Virus Infection pipeline report maps a dynamic development landscape with 10+ active companies working to advance 10+ pipeline therapies for BK Virus Infection treatment.
• Key companies operating in this space include SymBio Pharmaceuticals, AlloVir, Memo Therapeutics, Airis Cu, and others.
• Notable investigational therapies in development include MAU868, Brincidofovir, Posoleucel (ALVR105), Ciclosporin and Mycophenolate-mofetil, Tacrolimus and Mycophenolate-mofetil, and others.

Stay current with the most recent pipeline developments and emerging therapies in BK Virus Infection — get expert insights from DelveInsight: BK Virus Infection Treatment Drugs

Emerging Drug Profiles in the BK Virus Infection Pipeline

ALVR-105 (Posoleucel) — AlloVir

Posoleucel (ALVR-105), also known as Viralym-M, is a human leukocyte antigen (HLA)-matched, multi-virus-specific T-cell candidate developed by AlloVir. As the lead asset in AlloVir’s pipeline of allogeneic, off-the-shelf, multi-virus-specific T-cell therapies, Viralym-M is engineered to treat active virus-associated diseases in immunocompromised patients — including those following hematopoietic stem cell transplantation (HSCT), solid organ transplant, or individuals with primary immunodeficiencies, cancer, or HIV. The therapy targets a broad spectrum of viral pathogens including BK hemorrhagic cystitis, cytomegalovirus, adenovirus, Epstein-Barr virus, JC virus, and human herpesvirus 6. Posoleucel is currently advancing through Phase III clinical development for the treatment of BK virus infection.

Brincidofovir — SymBio Pharmaceuticals

Brincidofovir is an orally administered, broad-spectrum antiviral agent with demonstrated activity against multiple viruses, including BK virus. Clinical and preclinical studies have shown that Brincidofovir inhibits BK polyomavirus replication in primary human urothelial cells, pointing to its potential effectiveness in managing BK virus infections. The compound has also demonstrated promise in cases of BK virus-associated nephropathy following allogeneic hematopoietic stem cell transplantation. Brincidofovir is currently being assessed in a Phase II clinical trial for the treatment of BK Virus (BKV) infection.

Discover the groundbreaking therapies and clinical trials transforming the BK Virus Infection treatment landscape — access DelveInsight’s detailed report now: New BK Virus Infection Drugs

What the BK Virus Infection Pipeline Report Covers

The report delivers granular insights into companies developing BK Virus Infection therapies, with a full breakdown of pipeline assets per organization. Therapeutic candidates are segmented across early-, mid-, and late-stage development, with profiles encompassing both active and inactive (discontinued or dormant) programs. Drug assessments are structured by development stage, route of administration, target receptor, monotherapy or combination approach, mechanism of action, and molecular type. A detailed review of company-company and company-academia collaborations, licensing agreements, and financing activities shaping the future of the BK Virus Infection market is also included.

Leading Companies in the BK Virus Infection Space

SymBio Pharmaceuticals, AlloVir, Memo Therapeutics, Airis Cu, and additional emerging players actively contributing to this therapeutic area.

Therapeutic Assessment

By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical

By Molecule Type: Recombinant Fusion Proteins, Small Molecule, Monoclonal Antibody, Peptide, Polymer, Gene Therapy

By Product Type: Mono, Combination, Mono/Combination

By Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out what’s driving the future of BK Virus Infection treatment — explore pipeline developments, market dynamics, and key companies with DelveInsight: BK Virus Infection Market Drivers and Barriers

Scope of the BK Virus Infection Pipeline Report

• Geographic Coverage: Global
• Key Companies: SymBio Pharmaceuticals | AlloVir | Memo Therapeutics | AiCuris | Orthogon Therapeutics | Others
• Key Therapies: MAU868 | Brincidofovir | Posoleucel (ALVR105) | Ciclosporin + Mycophenolate mofetil | Tacrolimus + Mycophenolate mofetil | Others
• Assessment by Product Type: Monotherapy | Combination therapy | Mono/Combination
• Assessment by Clinical Stage: Discovery | Pre-clinical | Phase I | Phase II | Phase III

 

Access the most comprehensive insights on BK Virus Infection therapies, unmet needs, and pipeline players — download DelveInsight’s in-depth report today: BK Virus Infection Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. BK Virus Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. BK Virus Infection — DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. BK Virus Infection Collaboration Deals
9. Late-Stage Products (Phase III)
10. Mid-Stage Products (Phase II) — Brincidofovir: SymBio Pharmaceuticals
11. Early-Stage Products (Phase I)
12. Preclinical and Discovery Stage Products
13. Inactive Products
14. Key Companies
15. Key Products
16. Unmet Needs
17. Market Drivers and Barriers
18. Future Perspectives and Conclusion
19. Analyst Views
20. Appendix

About DelveInsight

DelveInsight is a premier healthcare-focused market research and consulting organization delivering high-quality market intelligence and strategic analysis to support evidence-based business decisions. With a team of seasoned industry specialists and deep expertise across life sciences and healthcare, the firm provides tailored research solutions to partners across the globe. Connect with DelveInsight to access accurate, real-time intelligence and stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com 

 

DelveInsight’s comprehensive report on “Microbiome Disease Pipeline Insights 2026” delivers extensive intelligence on over 140 companies and more than 180 investigational therapies currently advancing through development. This detailed examination encompasses drug candidate profiles across all developmental phases, from preclinical research through clinical trials. The assessment evaluates therapeutic candidates by product classification, developmental phase, administration method, and molecule type, while also documenting discontinued programs in this therapeutic area.

Discover the latest drugs and treatment options in the Microbiome Disease Pipeline @ https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight

Key Highlights from the Microbiome Disease Pipeline Analysis

• In March 2026, Microbiome Health Sciences initiated a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MHS-1031 effect on heartburn-free days in subjects with GERD-related heartburn symptoms.
• The current landscape shows a dynamic field with over 140 companies actively advancing more than 180 therapeutic candidates for Microbiome Disease management.
• Key pharmaceutical developers include MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences and others.
• Notable investigational therapies comprise Omadacycline Injection, Estrogen Cream, Altreno, Benzoyl peroxide, Mirabegron, Solifenacin, Dupilumab, and additional candidates.

Stay ahead with the most recent pipeline outlook for Microbiome Disease @ Microbiome Disease Treatment Drugs

Understanding Microbiome Disease

Microbiome refers to the collection of microbes and their interaction with the human body. Microbiome plays an important role in human physiology and disease. The microbes and their interaction with the human body demonstrate various aspects of human biology. The human body possesses numerous different species, particularly bacteria and fungi, which help in digesting food, preventing infections, and performing numerous life-supporting tasks. Microbes can also be harmful to their human hosts.

Featured Microbiome Disease Investigational Therapies

MaaT 013: MaaT Pharma

MaaT013 represents a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites). It aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). MaaT013 is an off-the-shelf, healthy-multi-donors-derived product intended for acute, hospital use. This compound is currently in Phase III development for treating Graft-versus-host disease.

QBKPN: Qu Biologics

QBKPN SSI represents a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs. The clinical trial is designed to assess QBKPN’s effectiveness in restoring innate immunity, preventing serious morbidity and mortality from respiratory infections, including COVID-19 and its variants, and reducing all-cause mortality. QBKPN SSI is designed to restore and enhance innate immune function, the body’s first line of defense against all infections and other diseases such as cancer. This compound is currently in Phase II development for treating immunodeficiency disorders.

BMC128: Biomica Ltd.

BMC128 represents a rationally-designed microbial consortium identified and selected through detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene’s MicroBoost AI platform. Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbour specific functional capabilities with potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes. Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a host’s microbial community with individually selected, cultured bacteria. This compound is currently in Phase I development for treating patients with colorectal cancer.

SER-155: Seres Therapeutics

SER-155 represents a consortium of bacterial species selected using Seres’ reverse translation discovery and development MbTx platform technologies. The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays, and in vivo disease models. The SER-155 composition is designed to prevent and decrease the colonization and abundance of bacterial pathogens that can harbor antibiotic resistance and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease bloodstream infection and GvHD incidence. SER-155 has received FDA Fast Track Designation. This compound is currently in Phase I development for treating patients with Bacteraemia.

MVT-201: Micro Viable Therapeutics

MVT-201 represents an orally administered capsule generated under cGMP conditions representing the complete gut microbiota of a clinically validated healthy donor and will enter clinical trials in 2024 for undisclosed targets. The lead product, MVT-201, is under evaluation at preclinical stage with positive results, and it is unique in its kind as a biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally designed and defined bacterial consortia that will be advanced with this funding. This investment will enable Microviable to consolidate growth and focus towards therapeutics, while increasing their facilities and headcount. This compound is currently in Preclinical development for treating patients with infectious diseases.

Explore groundbreaking therapies and clinical trials in the Microbiome Disease Pipeline @ New Microbiome Disease Drugs

Microbiome Disease Pipeline Report Coverage and Analysis

This comprehensive pipeline report delivers intelligence on:

• Detailed profiles of pharmaceutical companies developing Microbiome Disease therapeutics, including aggregate therapy portfolios from each organization.
• Assessment of therapeutic candidates classified by early-stage, mid-stage, and late-stage development phases.
• Active and inactive (dormant or discontinued) pipeline programs across participating companies.
• Categorization of investigational drugs by developmental stage, delivery route, target receptor, treatment approach (monotherapy or combination), mechanism of action, and molecular classification.
• In-depth examination of partnerships (industry collaborations and academic alliances), licensing arrangements, and funding details relevant to future market advancement.

Featured Companies

MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences and others.

Route of Administration 

Pipeline products are organized by delivery method:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecular Type 

Investigational products are categorized by molecular structure:

• Monoclonal antibody
• Small molecule
• Peptide

Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ Microbiome Disease Market Drivers and Barriers

Scope of the Microbiome Disease Pipeline Report

• Geographic Coverage: Global
• Featured Companies: MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences and others
• Pipeline Therapies: Omadacycline Injection, Estrogen Cream, Altreno, Benzoyl peroxide, Mirabegron, Solifenacin, Dupilumab, and others
• Product Type Assessment: Monotherapy, Combination therapy, Mono/Combination approaches
• Clinical Stage Assessment: Discovery, Preclinical, Phase I, Phase II, Phase III

Get the latest on Microbiome Disease Therapies and clinical trials @ Microbiome Disease Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Microbiome Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Microbiome Disease- DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. MaaT 013: MaaT Pharma
9. Drug name : Company name
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. QBKPN: Qu Biologics
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. BMC128: Biomica Ltd.
16. Drug name : Company name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. MVT-201: Micro Viable Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Microbiome Disease Key Companies
23. Microbiome Disease Key Products
24. Microbiome Disease- Unmet Needs
25. Microbiome Disease- Market Drivers and Barriers
26. Microbiome Disease- Future Perspectives and Conclusion
27. Microbiome Disease Analyst Views
28. Microbiome Disease Key Companies
29. Appendix

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us

Kanishk

kkumar@delveinsight.com 

DelveInsight’s “NSCLC Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Curious about the latest updates in the NSCLC Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

 

Key Takeaways from the NSCLC Pipeline Report

 

•  On April 07, 2026- Alliance Foundation Trials, LLC initiated a phase II design that provides a fairly rapid way to determine which of two potential neoadjuvant immunotherapy regimens holds the most promise for evaluation in a subsequent phase III trial against standard of care adjuvant immunotherapy. The AFT-16 trial of neoadjuvant atezolizumab in this setting provided proof of concept for safety of the neoadjuvant approach and for outcomes that compare favorably with standard of care therapy.
•  On April 07, 2026- Amgen conducted a phase 2 study to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
•  On April 06, 2026- Bristol-Myers Squibb initiated a phase 3 study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
•  On April 03, 2026- Servier Bio-Innovation LLC announced a a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.DelveInsight’s NSCLC Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for NSCLC treatment.
•  The leading NSCLC Companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
• Promising NSCLC Therapies such as Brigatinib, Tyrosine kinase inhibitor, AK104+anlotinib, Osimertinib, Gefitinib, SSGJ-707, JS111 capsules (AP-L1898), Atezolizumab, Tiragolumab, AK112, Pemetrexed, Paclitaxel and others.

 

Want to know which companies are leading innovation in NSCLC? Dive into the full pipeline insights @ NSCLC Clinical Trials Assessment

 

The NSCLC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The NSCLC Pipeline Report also highlights the unmet needs with respect to the NSCLC.

 

NSCLC Overview

 

Non-small cell lung cancer is the most common type of lung cancer. With this disease, cancer cells originate in your lung tissues. Non-small cell lung cancer grows slowly compared to small cell lung cancer but it often spreads to other parts of your body by the time it’s diagnosed. So, early detection and non-small cell lung cancer treatment are essential.

 

NSCLC Emerging Drugs Profile

 

 V940: Merck Sharp & Dohme LLC

 

V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.

 

 QL1706: Qilu Pharmaceutical Co., Ltd.

 

QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody that could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.

 

 Zenocutuzumab (MCLA-128): Merus N.V.

 

Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.

 

 ZW49: Zymeworks BC Inc.

 

ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload. A biparatopic (targeting two different non-overlapping epitopes on ERBB2, on extracellular domains 2 (ECD2) and 4 (ECD4). ZW25 is an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab. ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent eector function. ZW49 is in Phase I of clinical trials for the treatment of non-small cell lung cancer.

 

If you’re tracking ongoing NSCLC Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ NSCLC Treatment Drugs

 

The NSCLC Pipeline report provides insights into:-

 

•  The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
•  It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
•  NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
•  NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
•  Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market.

 

NSCLC Companies

 

Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.

 

The NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

 

•  Oral
•  Intravenous
•  Subcutaneous
•  Parenteral
•  Topical

 

NSCLC Products have been categorized under various Molecule types such as

 

•  Recombinant fusion proteins
•  Small molecule
•  Monoclonal antibody
•  Peptide
•  Polymer
•  Gene therapy

 

From emerging drug candidates to competitive intelligence, the NSCLC Pipeline Report covers it all – check it out now @ NSCLC Market Drivers and Barriers, and Future Perspectives

 

Scope of the NSCLC Pipeline Report

 

•  Coverage- Global
•  NSCLC Companies- Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
•  Promising NSCLC Therapies- Brigatinib, Tyrosine kinase inhibitor, AK104+anlotinib, Osimertinib, Gefitinib, SSGJ-707, JS111 capsules (AP-L1898), Atezolizumab, Tiragolumab, AK112, Pemetrexed, Paclitaxel and others.
•  NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
•  NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Stay ahead in Healthcare Research – discover what’s next for the NSCLC Treatment landscape in this detailed analysis @ NSCLC Emerging Drugs and Major Players

 

Table of Contents

 

•  Introduction
•  Executive Summary
•  Non-Small-Cell Lung cancer (NSCLC): Overview
•  Pipeline Therapeutics
•  Therapeutic Assessment
•  Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
•  Late Stage Products (Phase III)
•  V940: Merck Sharp & Dohme LLC
•  Drug profiles in the detailed report…..
•  Mid Stage Products (Phase II)
•  Zenocutuzumab (MCLA-128): Merus N.V.
•  Drug profiles in the detailed report…..
•  Early Stage Products (Phase I)
•  ZW49: Zymeworks BC Inc.
•  Drug profiles in the detailed report…..
•  Preclinical and Discovery Stage Products
•  Drug name: Company name
•  Drug profiles in the detailed report…..
•  Inactive Products
•  Non-Small-Cell Lung cancer (NSCLC) Key Companies
•  Non-Small-Cell Lung cancer (NSCLC) Key Products
•  Non-Small-Cell Lung cancer (NSCLC) – Unmet Needs
•  Non-Small-Cell Lung cancer (NSCLC) – Market Drivers and Barriers
•  Non-Small-Cell Lung cancer (NSCLC) – Future Perspectives and Conclusion
•  Non-Small-Cell Lung Cancer (NSCLC) Analyst Views
•  Non-Small-Cell Lung cancer (NSCLC) Key Companies
•  Appendix

 

About Us

 

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com 

 

DelveInsight’s “Glioma Pipeline Insight, 2026” report delivers detailed analysis on more than 180 companies and over 200 pipeline drugs in the glioma development landscape. It includes profiles of glioma pipeline drugs in clinical and preclinical phases. The report also evaluates glioma treatments by product type, development stage, delivery method, and molecular category. Additionally, it addresses discontinued pipeline candidates in this field.

Request a sample of the latest glioma drugs and therapies: https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Essential Highlights from the Glioma Pipeline Analysis

• On March 27, 2026 – Nationwide Children’s Hospital launched a phase 2 trial to evaluate the effectiveness of 1) ribociclib combined with everolimus for pediatric and young adult patients newly diagnosed with high-grade glioma (HGG), including DIPG, featuring genetic alterations in cell cycle or PI3K/mTOR pathways targeted by these agents, or 2) ribociclib with temozolomide for pediatric and young adult patients with diffuse hemispheric glioma (DHG), H3G34-mutant.
• On March 24, 2026 – Eli Lilly and Company started a study to assess the advantages of adding abemaciclib to temozolomide chemotherapy for newly diagnosed high-grade glioma after radiotherapy. Participation may extend around 11 months or more based on patient and tumor response.
• On March 23, 2026 – St. Jude Children’s Research Hospital began a clinical trial with two cohorts: Cohort 1 for patients with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG), and Cohort 2 for patients with NTRK1/2/3- or ROS1-fused CNS tumors excluding HGG.
• On March 20, 2026 – Daiichi Sankyo Co., Ltd. initiated a Phase 2 trial to examine the efficacy and safety of DS-1001b in patients with untreated IDH1-mutated WHO grade II glioma.
• On March 05, 2026 – Nuvation Bio Inc. commenced a phase 3 trial to investigate the efficacy, safety, and pharmacokinetic profile of safusidenib in participants with recurrent or progressive IDH1-mutant WHO Grade 2 or 3 glioma.
• DelveInsight’s glioma pipeline analysis reveals a dynamic field with 180+ active developers pursuing 200+ therapies for glioma.
• Top glioma developers include CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and more.
• Notable glioma candidates: DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, among others.

Gain access to clinical trials, novel therapies, and top developers via DelveInsight: https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

This glioma pipeline report offers a disease summary, development landscape, and evaluation of leading therapies. It also identifies key unmet needs in glioma management.

Understanding Glioma

Glioma refers to tumors originating in glial cells of the brain or spinal cord, supportive elements of the nervous system. These are classified by glial cell type, such as astrocytes, oligodendrocytes, or ependymal cells. Gliomas range from low-grade (indolent) to high-grade (aggressive and malignant). They represent the primary type of CNS tumor from glial origins.

Profiles of Promising Glioma Therapies

• AV-GBM-1: Aivita Biomedical, Inc.

AV-GBM-1 is a cutting-edge immunotherapy from AIVITA Biomedical, Inc., tailored for glioblastoma (GBM), a highly aggressive brain cancer. It employs patient-derived dendritic cells loaded with neoantigens from tumor-initiating cells, delivered via subcutaneous injections to boost immune attack on personalized cancer cells. It is currently in Phase III trials for glioma.

• DB 107: Denovo BioPharma

DB 107 from Denovo BioPharma is an experimental gene therapy for high-grade gliomas, including GBM. It uses a biomarker-driven strategy with Denovo Genomic Marker 7 (DGM7) to select responsive patients. The drug is in Phase II development for glioma.

• MDNA55: Medicenna Therapeutics, Inc.

MDNA55 targets recurrent glioblastoma multiforme (rGBM), a lethal brain cancer. This IL-4 Superkine delivers a bacterial toxin selectively to tumor cells overexpressing IL-4R, eliminating bulk tumors, disrupting support structures, and stimulating immunity. As a molecular trojan horse, it fuses permuted IL-4 with pseudomonas exotoxin A, ensuring tumor-specific action via endocytosis and apoptosis. Healthy brain cells remain safe. It is in Phase II for glioma.

• Abemaciclib: Eli Lilly and Company

Abemaciclib is a CDK4/6 inhibitor promoting cell cycle regulation to curb cancer growth. Used alone or with fulvestrant post-other therapies, it improves outcomes in HR+/HER2- breast cancer and is trialed for melanoma, lymphoma, solid tumors, and glioblastoma.

• NMS-03305293: Nerviano Medical Sciences

NMS-293 is a next-gen PARP1-selective inhibitor with low PARP2 activity and minimal DNA trapping, reducing toxicity and enabling combos with DNA-damaging agents. It excels in BBB penetration for CNS tumors/brain mets, showing strong activity in BRCA-mutated models and synergy with chemo. In Phase II with temozolomide for recurrent glioblastoma.

• CAN-3110: Candel Therapeutics

CAN-3110 is a novel replication-competent HSV-1 oncolytic virus with oncolytic and immune-activating effects, triggered by Nestin in cancer cells. In Phase I (investigator-sponsored) for recurrent HGG.

• MB-101: Mustang Bio

MB-101 is an IL13R2-specific CAR T-cell therapy from Mustang Bio for recurrent GBM and high-grade gliomas. In Phase I trials.

Discover innovative treatments and trials: https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Key Insights from the Glioma Pipeline Report

• Detailed profiles of companies advancing glioma therapies, including aggregate pipelines.
• Segmentation of candidates by early-, mid-, and late-stage development.
• Active and inactive (discontinued/dormant) projects from glioma developers.
• Breakdown by stage, ROA, target, mono/combo use, mechanism, and molecule type.
• In-depth review of partnerships (company-company, company-academia), licensing, and funding for market growth.

Major Glioma Developers

CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.

Pipeline drugs categorized by Route of Administration:

• Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal.

By Molecule Type:

• Oligonucleotide, Peptide, Small molecule.

Expert analysis on drivers and challenges: https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Report Scope

• Coverage: Global
• Glioma Developers: CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, etc.
• Glioma Pipeline Drugs: DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and more.
• Assessment by Product Type: Mono, Combination, Mono/Combination
• Assessment by Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Secure the detailed pipeline report now: https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

• Introduction
• Executive Summary
• Glioma: Disease Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• DelveInsight’s Analytical View on Glioma
• Late Stage (Phase III)
• AV-GBM-1: Aivita Biomedical, Inc.
• Detailed drug profiles…
• Mid Stage (Phase II)
• DB 107: Denovo BioPharma
• Detailed drug profiles…
• Early Stage (Phase I)
• MB-101: Mustang Bio
• Preclinical Products
• Drug Name: Company Name
• Detailed drug profiles…
• Inactive Products
• Key Glioma Developers
• Key Glioma Products
• Unmet Needs in Glioma
• Market Drivers and Barriers
• Future Perspectives and Conclusion
• Analyst Opinions
• Key Companies
• Appendix

About DelveInsight

DelveInsight is a premier healthcare market research and consulting provider, delivering high-quality intelligence and analysis for strategic decisions. Our expert team serves global clients in life sciences and healthcare with tailored insights.

Contact Us

Kanishk

kkumar@delveinsight.com 

According to DelveInsight’s comprehensive evaluation, the global Primary Myelofibrosis pipeline comprises over 55 key pharmaceutical organizations actively working toward developing 55+ Primary Myelofibrosis treatment therapies. This extensive analysis examines Clinical Trials, Therapeutic Candidates, Mechanism of Action, Route of Administration, and Development milestones.

The Primary Myelofibrosis Pipeline report encompasses thorough commercial and clinical evaluation of pipeline products spanning from pre-clinical developmental phases to the marketed stage. The report delivers detailed descriptions of therapeutic candidates, including mechanisms of action, clinical investigation data, NDA approvals (where applicable), and product development activities encompassing technology platforms, collaborations, mergers and acquisitions, funding initiatives, regulatory designations, and other product-related developments.

DelveInsight’s “Primary Myelofibrosis Pipeline Insight, 2026” report presents comprehensive intelligence into the current clinical development landscape and growth potential across the Primary Myelofibrosis Market.

Access a Free Sample PDF Report to discover more about Primary Myelofibrosis Pipeline Therapeutic Assessment at https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Major Highlights from the Primary Myelofibrosis Pipeline Report:

• Organizations worldwide are diligently advancing novel Primary Myelofibrosis treatment therapies with considerable achievements throughout recent years.
• Leading Primary Myelofibrosis pharmaceutical companies engaged in therapeutic development include Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, among others.
• Promising Primary Myelofibrosis therapies progressing through various clinical trial phases include LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others, anticipated to create substantial impact on the Primary Myelofibrosis marketplace in upcoming years.
• In March 2026, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-phase pharmaceutical organization specializing in innovative oncology therapies, revealed topline findings from its Phase 3 SENTRY investigation. This randomized, double-masked, placebo-controlled study assessed 60 mg selinexor combined with ruxolitinib in frontline myelofibrosis participants (n=353). The investigation successfully achieved its first co-primary objective, demonstrating statistically significant enhancement in spleen volume reduction of 35% or greater (SVR35) among individuals receiving the selinexor and ruxolitinib combination. The combination therapy demonstrated rapid, profound, and sustained reductions in spleen volume.
• In March 2026, China’s National Medical Products Administration (NMPA) granted approval to Sino Biopharmaceutical Ltd.’s rovadicitinib, marketed as Anxu, for utilization as first-line treatment in adult individuals with intermediate- or high-risk primary myelofibrosis. This encompasses patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Primary Myelofibrosis Disease Summary

Primary Myelofibrosis (PMF) represents a rare hematological malignancy classified under myeloproliferative neoplasms. It is distinguished by abnormal proliferation of bone marrow stem cells, resulting in fibrosis (scarring) of the bone marrow, which compromises normal blood cell production.

As the condition advances, the organism compensates by producing blood cells in alternative organs, particularly the spleen, causing splenomegaly (enlarged spleen). Prevalent symptoms encompass fatigue, anemia, weakness, weight reduction, night sweats, and bone pain.

Explore the latest Primary Myelofibrosis pipeline intelligence 2026, including emerging therapeutics, clinical investigations, and market opportunities. Stay ahead in Primary Myelofibrosis Clinical Trials at https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Emerging Primary Myelofibrosis Therapeutic Candidates Under Various Clinical Development Phases Include:

• JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis
• INREBIC (fedratinib): Bristol Myers Squibb
• XPOVIO (selinexor): Karyopharm Therapeutics
• RYTELO (imetelstat): Geron Corporation
• REBLOZYL (luspatercept/ACE-536): Bristol Myers Squibb
• Navtemadlin (KRT-232): Kartos Therapeutics
• Pelabresib (DAK539): Novartis
• Bomedemstat (IMG-7289/MK-3543): Merck
• TL-895: Telios Pharma
• RVU120 (SEL-120): Ryvu Therapeutics
• TP-3654 (nuvisertib): Syntara
• DISC-0974: Disc Medicine
• ELZONRIS (tagraxofusp/SL-401): Menarini Group

Primary Myelofibrosis Administration Routes

Primary Myelofibrosis pipeline report presents therapeutic evaluation of pipeline candidates by Administration Route. Products are classified under various ROAs, including:

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Primary Myelofibrosis Molecular Classifications

Primary Myelofibrosis Products are categorized under various Molecular classifications, including:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Primary Myelofibrosis Pipeline Therapeutics Evaluation

• Primary Myelofibrosis Evaluation by Product Classification
• Primary Myelofibrosis By Development Stage and Product Classification
• Primary Myelofibrosis Evaluation by Administration Route
• Primary Myelofibrosis By Development Stage and Administration Route
• Primary Myelofibrosis Evaluation by Molecular Classification
• Primary Myelofibrosis by Development Stage and Molecular Classification

DelveInsight’s Primary Myelofibrosis Report encompasses approximately 55+ products under various clinical development phases including:

• Late-phase products (Phase III)
• Mid-phase products (Phase II)
• Early-phase product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Additional Primary Myelofibrosis product details are presented in the report. Download the Primary Myelofibrosis pipeline report to discover more about emerging Primary Myelofibrosis therapeutics at https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Leading Organizations in the Primary Myelofibrosis Therapeutics Market Include:

Key pharmaceutical organizations developing therapies for Primary Myelofibrosis are Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., among others.

Primary Myelofibrosis Pipeline Analysis Delivers Intelligence Into:

• The report presents comprehensive intelligence about organizations developing therapies for Primary Myelofibrosis treatment with aggregate therapeutics created by each organization for the same condition.
• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Primary Myelofibrosis Treatment.
• Primary Myelofibrosis key pharmaceutical organizations engage in targeted therapeutic creation with corresponding active and inactive (dormant or discontinued) initiatives.
• Primary Myelofibrosis candidates under development classified by developmental phase, administration route, target receptor, monotherapy or combination approach, various action mechanisms, and molecular classification.
• Comprehensive examination of partnerships (organization-organization partnerships and organization-academia partnerships), licensing arrangements and funding details for future progression of the Primary Myelofibrosis marketplace.

The report is constructed utilizing data and intelligence traced from the researcher’s proprietary databases, organization/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from organization/university websites and industry-specific third-party sources.

Download Sample PDF Report to discover more about Primary Myelofibrosis therapeutic candidates and therapies at https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Primary Myelofibrosis Pipeline Market Catalysts

• Enhancement in R&D for the creation of novel and effective therapeutic candidates for treatment – Increasing occurrence in elderly populations, creation of biological therapies or immunotherapies are among the significant factors fueling the Primary Myelofibrosis Market.

Primary Myelofibrosis Pipeline Market Obstacles

• However, adverse effects associated with therapeutic candidates, elevated cost of therapy and additional factors are creating obstacles in the Primary Myelofibrosis Market expansion.

Range of Primary Myelofibrosis Pipeline Drug Intelligence

• Coverage: Global
• Key Primary Myelofibrosis Organizations: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, among others
• Key Primary Myelofibrosis Therapeutics: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, among others
• Primary Myelofibrosis Therapeutic Evaluation: Primary Myelofibrosis current marketed and Primary Myelofibrosis emerging therapeutics
• Primary Myelofibrosis Market Dynamics: Primary Myelofibrosis market catalysts and Primary Myelofibrosis market obstacles

Request Sample PDF Report for Primary Myelofibrosis Pipeline Evaluation and clinical investigations at https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Table of Content

1. Primary Myelofibrosis Report Introduction
2. Primary Myelofibrosis Executive Summary
3. Primary Myelofibrosis Overview
4. Primary Myelofibrosis- Analytical Perspective In-depth Commercial Assessment
5. Primary Myelofibrosis Pipeline Therapeutics
6. Primary Myelofibrosis Late Stage Products (Phase II/III)
7. Primary Myelofibrosis Mid Stage Products (Phase II)
8. Primary Myelofibrosis Early Stage Products (Phase I)
9. Primary Myelofibrosis Preclinical Stage Products
10. Primary Myelofibrosis Therapeutics Assessment
11. Primary Myelofibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Primary Myelofibrosis Key Companies
14. Primary Myelofibrosis Key Products
15. Primary Myelofibrosis Unmet Needs
16. Primary Myelofibrosis Market Drivers and Barriers
17. Primary Myelofibrosis Future Perspectives and Conclusion
18. Primary Myelofibrosis Analyst Views
19. Appendix
20. About DelveInsight

About DelveInsight

DelveInsight is a premier Business Consultant and Market Research organization focused exclusively on life sciences. It supports Pharmaceutical organizations by delivering comprehensive end-to-end solutions to enhance their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business expansion and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com 

 

DelveInsight’s analysis, “Malignant Ascites Pipeline Insight 2026,” presents comprehensive evaluation of over 5 organizations and more than 5 investigational therapeutic agents influencing the malignant ascites pipeline ecosystem. This analysis provides extensive profiles of pipeline candidates spanning clinical and preclinical development phases. It additionally assesses the therapeutic landscape according to product classification, development phase, route of administration (ROA), and molecular classification, while simultaneously identifying terminated or dormant programs within this therapeutic area.

Discover the most recent innovations in malignant ascites research and development. Obtain comprehensive intelligence regarding our advancing pipeline ecosystem @ Malignant Ascites Pipeline Outlook

Primary Insights from the Malignant Ascites Pipeline Analysis

• On February 09, 2026, Dong sheng Zhang launched a Phase II expansion investigation to evaluate the safety and therapeutic efficacy of liposomal irinotecan, administered either as monotherapy or combined with recombinant modified human tumor necrosis factor or bevacizumab, for managing malignant peritoneal effusion in subjects demonstrating resistance to conventional treatment approaches.
• DelveInsight’s evaluation reveals a robust pipeline, featuring more than 5 active organizations progressing over 5 investigational therapeutic agents targeting malignant ascites management.
• Leading industry participants within this domain include Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, among others.
• Notable therapeutics in development encompass M701, Paracentesis, Alfapump, and additional innovative candidates.

Remain informed regarding the most recent therapeutic developments in malignant ascites. Access comprehensive intelligence and participate in the transformation of treatment strategies @ Malignant Ascites Clinical Trials Assessment

Malignant Ascites Disease Overview

Ascites designates the pathological accumulation of fluid within the peritoneal cavity. When this manifestation develops secondary to malignancy, it is classified as malignant ascites. This condition demonstrates frequent association with malignancies including colorectal, breast, pulmonary, pancreatic, hepatic cancers, and lymphoma. Approximately 50% of subjects with malignant ascites present with peritoneal carcinomatosis, whereas roughly 13% develop this condition due to extensive hepatic metastases resulting in portal hypertension.

The condition may develop through various pathophysiological mechanisms, encompassing obstruction of lymphatic drainage secondary to tumor proliferation, excessive fluid secretion by aggressive malignancies, or development of functional cirrhosis resulting from widespread hepatic metastases. Malignant ascites correlates with unfavorable clinical prognosis, with median survival duration typically spanning 1 to 4 months.

Investigational Therapeutics for Malignant Ascites

SCB-313: Clover Biopharmaceuticals

Utilizing its proprietary Trimer-Tag™ platform, Clover Biopharmaceuticals has engineered SCB-313, a structurally sophisticated trimeric fusion protein designed to replicate native biological function. In contrast to traditional dimeric antibody-based therapeutic approaches, this innovative candidate demonstrates differentiated functional characteristics. SCB-313 is under investigation for managing malignant ascites, malignant pleural effusion (MPE), and peritoneal carcinomatosis, addressing considerable unmet therapeutic requirements in intracavitary malignancies. This therapeutic agent is presently advancing through Phase I clinical assessment.

Investigate investigational therapeutic opportunities and pipeline developments in malignant ascites @ Malignant Ascites Unmet Needs

Leading Organizations in the Malignant Ascites Therapeutic Arena

Primary organizations engaged in developing therapeutics for malignant ascites management include Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, among others.

Therapeutic Evaluation by Administration Route (ROA)

Pipeline therapeutic candidates are classified according to their administration routes, encompassing:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Therapeutic Evaluation by Molecular Classification

Malignant ascites pipeline candidates are additionally categorized by molecular classification, including:

• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies

Uncover ongoing developments influencing the malignant ascites treatment ecosystem and future trajectory @ Malignant Ascites Market Drivers and Barriers, and Future Perspectives

Report Coverage Scope

• Geographic Coverage: Global
• Key Organizations: Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, among others
• Key Therapeutic Candidates: M701, Paracentesis, Alfapump, among additional agents
• Evaluation by Product Classification: Monotherapy, Combination, and Mono/Combination
• Evaluation by Development Phase: Discovery, Preclinical, Phase I, Phase II, Phase III

For extensive intelligence regarding pipeline developments and future opportunities, access the comprehensive analysis @ Malignant Ascites Emerging Drugs and Companies

Report Structure

1. Introduction
2. Executive Summary
3. Malignant Ascites Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. DelveInsight Analytical Perspective
7. Mid-Stage Products (Phase II)
8. Drug Profiles
9. Early-Stage Products (Phase I)
10. SCB-313: Clover Biopharmaceuticals
11. Inactive Products
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com 

 

According to DelveInsight’s evaluation, the global AL Amyloidosis pipeline comprises over 10 major organizations actively engaged in developing more than 10 therapeutic interventions for AL Amyloidosis management, encompassing analysis of Clinical Studies, Therapeutic Candidates, Mechanisms of Action, Administration Routes, and Development Progress, as analyzed by DelveInsight.

DelveInsight’s “AL Amyloidosis Pipeline Insight, 2026” analysis delivers comprehensive intelligence regarding the current clinical development landscape and expansion opportunities throughout the AL Amyloidosis therapeutic market.

The AL Amyloidosis Pipeline analysis encompasses extensive commercial and clinical evaluation of pipeline candidates spanning from pre-clinical development phases through marketed stages. This analysis additionally provides detailed characterization of therapeutic agents, including drug mechanisms of action, clinical investigations, NDA approvals (where applicable), and development activities encompassing technology platforms, partnerships, mergers and acquisitions, funding rounds, regulatory designations, and additional product-specific information.

Primary Insights from the AL Amyloidosis Pipeline Analysis:

• Organizations worldwide are actively pursuing the development of innovative AL Amyloidosis therapeutic interventions, achieving substantial progress throughout recent years.
• AL Amyloidosis-focused organizations operating within the treatment landscape include HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, among others, advancing therapeutics for AL Amyloidosis management.
• Investigational AL Amyloidosis candidates across various clinical trial phases include LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and additional agents anticipated to substantially influence the AL Amyloidosis therapeutic market in upcoming years.
• In March 2026, Immix Biopharma, Inc. (NASDAQ: IMMX) disclosed completion of patient recruitment for its Phase II NEXICART-2 investigation, evaluating the CAR-T therapeutic NXC-201 in subjects with relapsed or refractory AL amyloidosis. The organization expects to announce preliminary data from this 40-participant study during the third quarter of 2026, followed by submission of a Biologics License Application (BLA) to the FDA, as stated in a corporate announcement.

AL Amyloidosis Disease Overview

AL amyloidosis (alternatively termed light chain amyloidosis) represents a rare and severe disorder resulting from the accumulation of aberrant proteins designated amyloid light chains within organs and tissues. These proteins originate from dysfunctional plasma cells within bone marrow and may deposit in cardiac tissue, kidneys, liver, and neural structures, resulting in organ impairment. Clinical manifestations vary according to affected organs and may encompass fatigue, edema, respiratory difficulty, and cardiac rhythm abnormalities. Prompt diagnosis and therapeutic intervention—frequently incorporating chemotherapy or stem cell transplantation—prove critical to preventing irreversible organ damage and optimizing clinical outcomes.

Access a Complimentary Sample PDF Report for additional information regarding AL Amyloidosis Pipeline Therapeutic Evaluation- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Investigational AL Amyloidosis Therapeutics Across Various Clinical Development Phases Include:

• LambdaMab: HaemaLogiX
• ZN d5: Zentalis Pharmaceuticals
• STI-6129: Sorrento Therapeutics
• Isatuximab: Sanofi
• Bendamustine: Astellas Pharma GmbH
• Belantamab mafodotin: GlaxoSmithKline
• Ixazomib: Takeda Oncology
• CAEL-101: Caelum Biosciences

AL Amyloidosis Administration Routes

The AL Amyloidosis pipeline analysis delivers therapeutic evaluation of pipeline candidates by Administration Route. Therapeutics have been classified under various administration routes, including:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

AL Amyloidosis Molecular Classifications

AL Amyloidosis therapeutic candidates have been categorized under various molecular classifications, including:

• Oligonucleotide
• Peptide
• Small molecule

AL Amyloidosis Pipeline Therapeutic Evaluation

• AL Amyloidosis Evaluation by Product Classification
• AL Amyloidosis By Development Phase and Product Classification
• AL Amyloidosis Evaluation by Administration Route
• AL Amyloidosis By Development Phase and Administration Route
• AL Amyloidosis Evaluation by Molecular Classification
• AL Amyloidosis by Development Phase and Molecular Classification

DelveInsight’s AL Amyloidosis Analysis encompasses approximately 10+ therapeutic candidates across various clinical development phases including:

• Late-stage candidates (Phase III)
• Mid-stage candidates (Phase II)
• Early-stage candidates (Phase I)
• Pre-clinical and Discovery phase candidates
• Discontinued & Inactive candidates
• Administration Route

Additional AL Amyloidosis therapeutic details are presented in the comprehensive analysis. Access the AL Amyloidosis pipeline analysis to discover more regarding investigational AL Amyloidosis therapeutics https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Leading Organizations in the AL Amyloidosis Therapeutics Landscape Include:

Primary organizations developing therapeutics for AL Amyloidosis management include Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, among others.

AL Amyloidosis Pipeline Intelligence:

The AL Amyloidosis pipeline analysis delivers intelligence regarding:

• This analysis offers comprehensive insights concerning organizations developing therapeutics for AL Amyloidosis management, including aggregate therapeutic candidates developed by individual organizations.
• It evaluates diverse therapeutic candidates categorized into early-stage, mid-stage, and late-stage development for AL Amyloidosis treatment.
• AL Amyloidosis key organizations are engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) programs.
• AL Amyloidosis therapeutic candidates in development classified by developmental phase, administration route, target receptor, monotherapy versus combination therapy, mechanism of action, and molecular classification.
• Comprehensive evaluation of partnerships (company-to-company and company-to-academia collaborations), licensing agreements, and financing particulars for future advancement of the AL Amyloidosis therapeutic market.

The analysis is constructed utilizing data and intelligence obtained from the researcher’s proprietary databases, organizational/institutional websites, clinical trial registries, conferences, SEC filings, investor presentations, and published press releases from organizational/institutional websites and industry-specific third-party sources.

Access Sample PDF Report for additional information regarding AL Amyloidosis therapeutics and interventions https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

AL Amyloidosis Pipeline Market Growth Drivers

• Elevation in patient population affected by AL Amyloidosis, enhanced disease awareness represent significant factors propelling the AL Amyloidosis therapeutic market.

AL Amyloidosis Pipeline Market Challenges

• Nevertheless, elevated costs of associated therapeutic interventions, adverse effects associated with treatments, and additional factors present obstacles to AL Amyloidosis market expansion.

AL Amyloidosis Pipeline Drug Intelligence Coverage

• Coverage: Global
• Key AL Amyloidosis Organizations: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, among others
• Key AL Amyloidosis Candidates: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and additional therapeutics
• AL Amyloidosis Therapeutic Evaluation: AL Amyloidosis currently marketed and AL Amyloidosis investigational therapeutics
• AL Amyloidosis Market Dynamics: AL Amyloidosis market growth drivers and AL Amyloidosis market challenges

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com 

Healthcare delivery is undergoing unprecedented transformation driven by cellular regeneration science. Organizations and researchers globally are harnessing the remarkable potential of Stem Cell Companies dedicated to advancing therapeutic possibilities. These pioneering enterprises are developing innovative solutions for conditions that have historically challenged conventional medical approaches. The momentum surrounding this sector reflects genuine scientific achievement and authentic patient demand for more effective treatment modalities that address underlying disease mechanisms rather than merely managing symptoms.

Understanding Cellular Potential and Biological Mechanisms

The scientific community has made remarkable strides in comprehending Stem Cell biology and practical applications. These extraordinary cellular components possess intrinsic abilities to self-regenerate and transform into specialized tissue varieties, creating unprecedented opportunities for treating degenerative conditions, traumatic injuries, metabolic disorders, and various malignancies. The accelerating research momentum demonstrates scientific consensus regarding the profound therapeutic value these cellular interventions can provide. Investment dollars, talented researchers, and institutional resources continue flowing into this promising domain at an accelerating pace.

Market Expansion and Commercial Growth Dynamics

The commercial landscape demonstrates impressive financial performance and robust growth projections. The Stem Cell Market Size reflects substantial economic expansion, with financial forecasts indicating considerable market valuations throughout the forthcoming years. Several converging factors drive this expansion including heightened healthcare expenditures, mounting chronic disease incidence, and sustained governmental investment in regenerative medicine initiatives. The economic performance validates stakeholder confidence in the sector’s long-term sustainability and transformative potential for healthcare systems worldwide.

Clinical Advancement and Treatment Development Progress

Exciting developments characterize the research landscape as Stem Cell Pipeline candidates progress through rigorous evaluation stages. Numerous promising interventions advance through preliminary assessments, formal regulatory reviews, and comprehensive clinical examinations involving human participants. These emerging treatments target blood-related malignancies, autoimmune pathologies, organ dysfunction, and neurological complications. The expanding therapeutic portfolio demonstrates meaningful scientific progress addressing critical patient needs, offering genuine alternatives where treatment options previously remained severely limited or nonexistent.

Disease Burden and Population Health Considerations

Understanding Stem Cell Market Epidemiology patterns provides valuable context for market opportunities and research prioritization. Epidemiological evidence reveals escalating burdens from aging-related deterioration, lifestyle-induced pathologies, demographic shifts toward older populations, and prevalent conditions lacking sufficient therapeutic interventions. This epidemiological landscape underscores critical necessity for breakthrough approaches capable of addressing widespread healthcare challenges affecting billions of individuals across diverse geographic regions and socioeconomic circumstances.

Leading Organizations and Competitive Landscape

The sector encompasses ambitious Stem Cell enterprises driving scientific innovation and commercial advancement. Organizations including Osiris Therapeutics, Lineage Cell Therapeutics, Geron Corporation, and NorthStar Medical Radiographics spearhead groundbreaking research and sophisticated manufacturing capabilities. These institutions invest substantially in cutting-edge facilities, extensive clinical investigations, and strategic commercialization approaches. The competitive terrain features fierce competition between multinational pharmaceutical conglomerates and nimble biotechnology innovators pursuing market leadership and therapeutic breakthroughs.

Financial Projections and Market Valuation Trends

Economic analysis indicates impressive expansion throughout the Stem Cell Market landscape. Financial projections suggest substantial value creation and revenue generation throughout the coming decade. Multiple drivers propel this economic expansion including escalating healthcare investments, increasing disease prevalence, robust research funding, and growing patient awareness. The financial outlook demonstrates strong institutional confidence in commercial viability, with investors allocating significant capital to companies positioned at the forefront of therapeutic development and market commercialization.

Regulatory Pathways and Approval Considerations

Governance frameworks surrounding cellular therapeutics demonstrate considerable variation internationally. Regulatory authorities worldwide continue refining sophisticated approval structures that simultaneously protect patient welfare and promote scientific advancement. This balanced regulatory philosophy proves essential for maintaining public trust while enabling rapid therapeutic deployment. Successfully navigating approval requirements remains crucial for enterprises engaged in research activities and commercial market entry strategies.

Envisioning Healthcare’s Future Trajectory

The cellular medicine revolution holds extraordinary promise for healthcare transformation. With escalating financial commitments, dedicated organizational champions, advancing therapeutic candidates, and compelling epidemiological justification, the sector demonstrates exceptional growth potential. As scientific knowledge deepens and supporting clinical evidence accumulates, cellular-based treatments will increasingly become standard clinical practice across multiple disease categories, fundamentally enhancing patient outcomes and transforming healthcare delivery globally.

Latest Reports Offered by Delveinsight

stem cell market | pigment epithelial detachment market | temporomandibular disorders market | catheter stabilization devices market | phototherapies for psoriasis market | sepsis market | vascular grafts market | urea cycle disorders market | asperger syndrome market | coronary angioplasty market | neuroendocrine tumors market | vital sign monitors devices market | avascular necrosis market | diabetic retinopathy market | dyspepsia market | membranous nephropathy market | nocturia market | radiation dermatitis market | synovial sarcoma market | thrombectomy devices market | transmucosal drug delivery devices market | urinary retention market | ascites market | b cell lymphomas market | central retinal vein occlusion market | complex regional pain syndrome market | cranial & auricular electrotherapy stimulation devices market | diabetic wound market | digestive system fistula market | endoscopic ultrasound market | familial adenomatous polyposis market | familial lipoprotein lipase deficiency market | herpes labialis market | hypoxic ischemic encephalopathy market | lactose intolerance market | lambert eaton myasthenic syndrome market | langerhans cell histiocytosis market | muscle spasticity market | nephropathic cystinosis market | obstructive sleep apnea market | oral electrolyte solutions market | pecoma market | pediatric brain tumor market | pelizaeus-merzbacher disease market | pelvic organ prolapse market | peripheral arterial disease market | post operative pain market | presbyopia market | pro-opiomelanocortin pomc deficiency obesity & leptin receptor lepr deficiency obesity market

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com